Clinical study on the effect of Shengxihuaxian recipe on serum exosome miRNA expression profile in patients with Idiopathic pulmonary fibrosis disease

注册号:

Registration number:

ITMCTR2200006584

最近更新日期:

Date of Last Refreshed on:

2022-09-12

注册时间:

Date of Registration:

2022-09-12

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

升陷化纤方对特发性肺纤维化患者血清外泌体miRNA表达谱影响的临床研究

Public title:

Clinical study on the effect of Shengxihuaxian recipe on serum exosome miRNA expression profile in patients with Idiopathic pulmonary fibrosis disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

升陷化纤方对特发性肺纤维化患者血清外泌体miRNA表达谱影响的临床研究

Scientific title:

Clinical study on the effect of Shengxihuaxian recipe on serum exosome miRNA expression profile in patients with Idiopathic pulmonary fibrosis disease

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200063572 ; ChiMCTR2200006584

申请注册联系人:

董亚伟

研究负责人:

刘喜平

Applicant:

Dong yawei

Study leader:

Liu Xiping

申请注册联系人电话:

Applicant telephone:

15639765830

研究负责人电话:

Study leader's telephone:

18919091650

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1358236476@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lxpd-257@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

甘肃省兰州市城关区定西东路35号

研究负责人通讯地址:

甘肃省兰州市城关区嘉峪关西路732号肺病科

Applicant address:

Gansu University of Traditional Chinese Medicine, No.35 Dingxi East Road, Chengguan District, Lanzhou City, Gansu Province

Study leader's address:

Department of pulmonary disease, Affiliated Hospital of Gansu University of Traditional Chinese medicine, No. 732 Jiayuguan West Road, Chengguan District, Lanzhou City, Gansu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

甘肃中医药大学

Applicant's institution:

Gansu University of Traditional Chinese medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2002-46

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

甘肃中医药大学附属医院伦理委员会

Name of the ethic committee:

People's Committee of Gansu University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/5/17 0:00:00

伦理委员会联系人:

马泉

Contact Name of the ethic committee:

Ma quan

伦理委员会联系地址:

甘肃省兰州市城关区嘉峪关西路732号

Contact Address of the ethic committee:

Affiliated Hospital of Gansu University of Traditional Chinese medicine, No. 732 Jiayuguan West Road, Chengguan District, Lanzhou City, Gansu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

甘肃中医药大学附属医院

Primary sponsor:

Affiliated Hospital of Gansu University of Traditional Chinese medicine

研究实施负责(组长)单位地址:

甘肃省兰州市城关区嘉峪关西路732号肺病科

Primary sponsor's address:

Department of pulmonary disease, Affiliated Hospital of Gansu University of Traditional Chinese medicine, No. 732 Jiayuguan West Road, Chengguan District, Lanzhou City, Gansu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

甘肃

市(区县):

兰州

Country:

China

Province:

Gansu

City:

Lanzhou

单位(医院):

甘肃中医药大学附属医院

具体地址:

甘肃省兰州市城关区嘉峪关西路732号

Institution
hospital:

Affiliated Hospital of Gansu University of Traditional Chinese medicine

Address:

Affiliated Hospital of Gansu University of Traditional Chinese medicine, No. 732 Jiayuguan West Road, Chengguan District, Lanzhou City, Gansu Province

经费或物资来源:

兰州市城关区科技计划项目

Source(s) of funding:

Lanzhou Chengguan District Science and technology plan project

研究疾病:

特发性肺纤维化

研究疾病代码:

Target disease:

IDiopathic pulmonary fibrosis

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.基于IPF临床患者血清中外泌体miRNA病症结合探讨中医证候; 2.初步探索IPF中医证候研究与血清外泌体标志物的关系。

Objectives of Study:

1.Exploring TCM evidence based on the combination of exosomal miRNA disease in clinical patients' serum 2.Preliminary exploration of the relationship between TCM evidence studies and serum exosome markers in IPF

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合IPF稳定期诊断的患者; (2)年龄50~80岁; (3)符合中医辨证诊断标准; (4)入选前1个月内未参加其他药物临床研究; (5)自愿接受治疗,并签署知情同意书。

Inclusion criteria

(1) Patients with stable IPF; (2) Aged 50-80 years; (3) In accord with the diagnostic criteria of TCM syndrome differentiation; (4) Not participate in any other interventional clinical trial within one month before selection; (5) Accept treatment voluntarily and sign the informed consent.

排除标准:

(1)妊娠或哺乳期妇女及近期有妊娠计划的患者; (2)神志不清、痴呆、各种精神疾病患者; (3)合并严重心功能不全、肝肾疾病、支气管哮喘、慢阻肺、神经系统疾病、肿瘤、胸廓畸形患者; (4)合并严重的关节、周围神经及周围血管病变影响肢体活动及长期卧床患者; (5)已知对治疗药物过敏者。 (6)排除气虚络瘀和阳虚寒凝患者。

Exclusion criteria:

1. Pregnant, breastfeeding women or patients with a recent pregnancy plan; 2. Delirious, dementia, or with any mental disorder; 3. Complicated with severe cardiac insufficiency, liver and kidney diseases, bronchial asthma, chronic obstructive pulmonary disease, tumor or thoracic deformity; 4. With a condition of limb dysfunction or bedridden; 5. Known to be allergic to any component of the therapeutic drugs 6.Exclude patients with Qi deficiency, stagnation and Yang deficiency and cold condensation

研究实施时间:

Study execute time:

From 2022-09-15

To      2023-09-15

征募观察对象时间:

Recruiting time:

From 2022-09-15

To      2023-12-15

干预措施:

Interventions:

组别:

气虚络阻

样本量:

32

Group:

Qi deficiency and collateral obstruction

Sample size:

干预措施:

干预措施代码:

Intervention:

nothing

Intervention code:

组别:

健康对照组

样本量:

20

Group:

Healthy control group

Sample size:

干预措施:

干预措施代码:

Intervention:

nothing

Intervention code:

样本总量 Total sample size : 52

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

甘肃

市(区县):

兰州

Country:

China

Province:

Gansu

City:

Lanzhou

单位(医院):

甘肃中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Gansu University of Traditional Chinese medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血清抗体

指标类型:

主要指标

Outcome:

serum antibody

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood serum

Tissue:

人体标本去向

使用后保存

说明

使用后保存三年

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 50
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

nothing

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以学术论文的形式进行公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be made public with academic papers

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有的原始数据填到CRF表中,在随机化电子系统中被第三方独立管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All the data will be recorded in the case record form as raw materials. The data will also be recorded in the electronic data capture with original records of allocations, and administered by a third party.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above